Filing Flows › Myriad Genetics (MYGN) › Q3 2025
Myriad Genetics (MYGN) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 4, 2025
Myriad Genetics (MYGN) reported revenue of $206M for the third quarter 2025 (Q3 2025), -4% from a year earlier and -3% from the quarter before. Operating margin was -11.3%, net loss $27.4M (13.3% of revenue).
Myriad Genetics, Q3 2025: revenue $206M (-4% year over year), operating margin -11.3%, net loss $27.4M, operating cash flow $21.1M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $206M | -3% | -4% |
| Operating profit | −$23.3M | — | — |
| Net earnings | −$27.4M | — | — |
| Operating cash flow | $21.1M | — | 30× |
| Free cash flow | $18.3M | — | — |
What changed
Revenue was $205.7M in Q3 2025, down 4% year over year and down 3% from the previous quarter. Hereditary Cancer was the largest line at 45% of revenue. Pharmacogenomics lost $9.0M year over year (down 19%), 118% of the total change.
Gross margin was 69.9%, down 0.3 points from a year earlier. Operating costs exceeded revenue by $23.3M, an operating margin of -11.3%. Operating expenses fell 2% while revenue fell 4%. The quarter ended with a net loss of $27.4M, narrower than the previous quarter's $330.5M loss.
Operating cash flow was $21.1M (up 2914% year over year). Non-cash charges added back $12.6M of depreciation and amortization and $12.2M of share-based compensation. Working capital and other items added $23.7M. Capital expenditures of $2.8M left free cash flow of $18.3M.
Questions
What was Myriad Genetics' revenue in the third quarter 2025?
Myriad Genetics (MYGN) reported revenue of $206M for the third quarter 2025 (Q3 2025), -4% from a year earlier and -3% from the quarter before.
Was Myriad Genetics profitable in the third quarter 2025?
Operating loss was $23.3M (-11.3% of revenue) and net loss $27.4M.
Source: Myriad Genetics 10-Q on SEC EDGAR.